Skip to content
Peptigraph home

MOTS-c and Tesamorelin Together: What Is Known

MOTS-c and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Mitochondrial-derived peptidePCAC voted 7–5 for 503A (Jul 2026)MOTS-cMitochondrial-derived peptide; human studies found only measured the body's own circulating levels (for example after repeated heat treatment), not administered MOTS-c.[5]GLP-1 & metabolicGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[20]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 1 result, 2 Oct 2026).

MOTS-c is not FDA approved, and we have no sourced data on combining it with Tesamorelin.
Each component

Side by side

Showing 13 of 14 fields where the two differ. Evidence strength are the same or both unknown.

FieldMOTS-cTesamorelin
ClassMitochondrial-derived peptideGHRH analog
Also calledmotstesa, Egrifta
CategoryGLP-1 & metabolicGrowth hormone
FDA statusPCAC voted 7–5 for 503A (Jul 2026)FDA approved (Egrifta)
PCAC vote, Jul 2026PCAC voted 7–5 for the 503A list (Jul 2026); not finalizedNot on the Jul 2026 agenda
WADAProhibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times.Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.
Anti-doping detection
  • A plasma (blood) test for MOTS-c has been validated to WADA standards.PMID 30394592
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeNo published half-life foundPubMed search, 2 Oct 202611 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Human studies we summarised7 human (4 randomized or controlled) of 15 summarised11 human (11 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold5 mg, 10 mg, 20 mg, 40 mg2 mg, 5 mg, 10 mg, 20 mg
US searches per month60,500 · +437% searches165,000 · +188% searches
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

MOTS-c vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison
ComparisonMOTS-c vs Tesamorelin

What people search

  • tesamorelin and mots c90/mo
  • mots c and tesamorelin90/mo
  • mots c and tesamorelin together70/mo
  • mots c tesamorelin50/mo
  • tesamorelin mots c stack40/mo
  • mots c with tesamorelin40/mo

US monthly searches, Google Keyword Planner, Oct 2026. Shown so you can see which questions this page answers.

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  3. 3World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  4. 4Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
  5. 5Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
  6. 6Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
  7. 7Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
  8. 8PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  14. 14Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  15. 15EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  16. 16The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  17. 17Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  18. 18The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  19. 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  20. 20Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  21. 21Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org

Found an error? Report a correction.